Literature DB >> 11377734

Interaction between angiotensin IV and adenosine A(1) receptor related drugs in passive avoidance conditioning in rats.

J Tchekalarova1, T Kambourova, V Georgiev.   

Abstract

The functional interaction between ANG (3--8) (ANG IV) and adenosine A(1) receptor related drugs in passive avoidance (step-through) task in rats was studied in Wistar rats. ANG IV exerted dose-dependent (inverted-U) improvement of the retention while sarilesin (an angiotensin II analog) impaired this effect. Co-administration of theophylline and ANG IV, both in ineffective doses, enhanced the retention. The selective adenosine A(1) receptor agonist cyclopentyladenosine (CPA) attenuated ANG IV-induced memory enhancement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377734     DOI: 10.1016/s0166-4328(01)00198-x

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  4 in total

1.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.

Authors:  Jessika Royea; Luqing Zhang; Xin-Kang Tong; Edith Hamel
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

Review 2.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

Review 3.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

4.  Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.

Authors:  Jean K Ho; Daniel A Nation
Journal:  Neurosci Biobehav Rev       Date:  2018-05-04       Impact factor: 8.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.